Loading...
Research Mentor Name
Dr. Vijaya Arun Kumar
Research Mentor Email Address
vkumar@med.wayne.edu
Institution / Department
Wayne State University School of Medicine
Document Type
Research Abstract
Research Type
clinicalresearch
Level of Research
no
Abstract
Catheter Directed Thrombolysis (CDT) or Systemic Thrombolysis (ST) are current standards of care for patients experiencing a Massive (MPE) or Submassive (SPE) Pulmonary Embolism which are categories that are defined by AHA guidelines for the Emergency Department. The Pulmonary Embolism Severity Index (PESI), a five-tier system, is a composite metric that can risk stratify PE into low risk (tiers 1,2) for SPE and high risk (tiers 3,4,5) for MPE, predicting mortality and outcomes. This study aims to determine if CDT or ST/no intervention (ST/NI) has better outcomes for MPE and SPE patients, while using PESI as a risk stratification tool. We conducted a retrospective analysis of patients from 2010 – 2016 who underwent CDT or ST/NI, matching patients using ten variables to yield N= 336: with equal proportions receiving CDT and ST/NI. 96 patients were in the low risk PESI group and 240 patients were in the high risk PESI group. In both low and high risk PESI groups, CDT intervention was associated with longer length of stay, (p
Disciplines
Analytical, Diagnostic and Therapeutic Techniques and Equipment | Medicine and Health Sciences
Recommended Citation
Patel, Dhruvil A.; Kumar, Vijaya Arun; and Reed, Brian, "Catheter Direct Thrombolysis as a Modality of Management for Pulmonary Embolism: Risk Stratifying with the Pulmonary Embolism Severity Index" (2021). Medical Student Research Symposium. 123.
https://digitalcommons.wayne.edu/som_srs/123
Comments
The authors would like to thank Dr. Mahir Elder M.D. for providing the data for the patients that underwent CDT treatment. We would also like to thank the Wayne State University School of Medicine Medical Student Research Fellowship program for providing a stipend while this research was being conducted. There are no other financial disclosures.